ATOSS SOFTWARE AG
Commented by Fabian Lorenz on July 30th, 2026 | 10:00 CEST
Analysts Turn Bullish: Multi-Bagger Potential? TeamViewer, Atoss Software and MustGrow Biologics
Created and Published on Behalf of MustGrow Biologics Corp.
GBC Research sees significant re-rating potential for MustGrow and its mustard-based biologicals platform. The analysts have set a price target of EUR 1.66, while the shares are currently trading at approximately EUR 0.19. By 2028, GBC forecasts earnings per share of CAD 0.11, excluding any potential profits from the company's collaboration with Bayer. For TeamViewer, analysts expect the second quarter of 2026 to mark the beginning of operational improvements, particularly in the enterprise customer segment, which they believe offers substantial growth potential. However, not all analysts share this optimistic view, with some remaining cautious on the German software company. Analysts are also bullish on Atoss Software. The key question now is whether the shares can climb to EUR 135.
Read